Craig Slingluff, MD
Enriched profileJoseph Helms Farrow Professor of Surgery, Vice Chair for Research · University of Virginia School of Medicine
Craig Slingluff is Joseph Helms Farrow Professor of Surgery, Vice Chair for Research at University of Virginia School of Medicine. OpenAlex indexes 614 publications with 21,443 citations (h-index 76); ClinicalTrials.gov lists 34 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Surgical Oncology profiles in the findmyKOL directory.
Data verified 18 Oct 2026
Overview
Updated 18 Oct 2026
Craig Slingluff, M.D., is Joseph Helms Farrow Professor of Surgery, Vice Chair for Research at University of Virginia School of Medicine, Department of Surgery. The public record shows 614 publications with 21,443 citations (h-index 76), centered on Cancer Immunotherapy and Biomarkers, Cutaneous Melanoma Detection and Management, Immunotherapy and Immune Responses. It also documents an investigator role on 34 registered clinical trials, industry payments reported by 2 companies, 15 NIH-funded awards (1992–2026).
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: Cancer Immunotherapy and Biomarkers
- 34 registered trials on ClinicalTrials.gov
- Open Payments reporting from 2 companies
Generated from the cited public record · current as of 18 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 41 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 235.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 18 Oct 2026
Listed as an investigator on 34 registered studies on ClinicalTrials.gov. The most recent:
- Excision of Lymph Node Trial (EXCILYNT) (Mel69)
Sponsor: Craig L Slingluff, Jr
- Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma
Sponsor: Craig L Slingluff, Jr
Industry payments
Updated 18 Oct 2026
2 companies reported payments to CMS in program years 2021–2024. These are public disclosures, not judgments. The latest:
- Iovance Biotherapeutics, Inc.Program year20241 payment
- CSL BehringProgram year20211 payment
NIH funding
Updated 18 Oct 2026
15 NIH research awards on record, funded 1992–2026 per NIH RePORTER. The latest:
- Postdoctoral Training Grant for MDs in Surgical Oncology Research
University of Virginia
FY2026$493,034T32CA163177 - Postdoctoral Training Grant for MDs in Surgical Oncology Research
University of Virginia
FY2025$382,378T32CA163177 - Postdoctoral Training Grant for MDs in Surgical Oncology Research
University of Virginia
FY2024$272,436T32CA163177
Congress activity
Updated 18 Oct 2026
47 congress contributions (2004–2025) across AACR, ASCO per OpenAlex. The most recent:
- Abstract 3541: A novel chimeric RNA as a source of neoantigens in CRC
AACR Annual Meeting
AACR2025Co-author - Lymph node excision (LNEx) for patients with stage III melanoma with one clinically positive node: Excision of Lymph Node trial (EXCILYNT).
ASCO Annual Meeting
ASCO2025Presenting author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 18 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Impact of GM-CSF and Two-Site Vaccination on Clinical Outcomes after Multipeptide Vaccination for Melanoma: Long-term Analysis of a Randomized Phase II Trial.
Clinical cancer research
Clinical Trial2026 - Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab).
Cancer research communications
Clinical Trial2026 - Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC).
Journal for immunotherapy of cancer
Clinical Trial2026
Most-cited works
by citation count (OpenAlex)- 01Tumor and Microenvironment Evolution during Immunotherapy with NivolumabArticle2,384 citations2017
- 02Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell RecruitmentArticle1,119 citations2009
- 03Potential Regulatory Function of Human Dendritic Cells Expressing Indoleamine 2,3-DioxygenaseArticle1,028 citations2002
- 04Identification of a Peptide Recognized by Five Melanoma-Specific Human Cytotoxic T Cell LinesArticle824 citations1994
- 05
Network
Updated 18 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 18 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/craig-slingluff-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
uvahealth.com/providers/Craig-Slingluff-1477687283
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uvahealth.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 18 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
University of Virginia School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uvahealth.com ↗ - BA
University of Virginia
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →uvahealth.com ↗
Editorial & leadership roles
journal and society appointments- Co-Chair
Melanoma Committee, Eastern Cooperative Oncology Group (ECOG)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.med.virginia.edu ↗ - Director
Surgical Oncology Research Training Program
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uvahealth.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uvahealth.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uvahealth.com ↗
Secondary affiliations
appointments beyond the home institution- Director
UVA Comprehensive Cancer Center Human Immune Therapy Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.virginia.edu ↗ - Co-Director
Focused Ultrasound Cancer Immunotherapy Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →eurekalert.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
William Petri, MD
University of Virginia School of Medicine
Robert Dreicer, MD
University of Virginia School of Medicine
Antonio Abbate, MD
University of Virginia School of Medicine
Larry Borish, MD
University of Virginia School of Medicine
Jedd Wolchok, MD
Weill Cornell Medicine
Frank Hodi, MD
Dana-Farber Cancer Institute
Mario Sznol, MD
University of Miami Miller School of Medicine
Igor Puzanov, MD
Roswell Park Comprehensive Cancer Center